[16] Wood DE, Kazerooni EA, Aberle DR, et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines®), lung cancer screening, version 2.2023[EB/OL]. (2023-05-27)[2023-06-23]. https://www.nccn.org/p...
[1]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Non-Small Cell Lung Cancer, Version 11.2024, October 15, 2024. 整理:王福栋;
Zhong Jiangtao, Zhou Shuihong. Interpretation of updated NCCN guidelines for head and neck cancer, version 1. 2023[J]. Journal of Practical Oncology, 2023, 38(3): 203-210. 头颈部癌是全世界第六种最常见的癌症[1]。2022年,约有66 ...
三、2024 Version 3 版本在 2024 Version 2 版本的基础上做了如下调整: NSCL-18 ►新增脚注 II:FDA 批准的生物类似物是合适的替代选择。 参考文献 [1] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Non-Small Cell Lung Cancer, Version 3.2024, March 12, 2024. 作者:黄玉庭;编辑...
(NCCN Guidelines®) for Lung Cancer Screening Version 2.2023 – May 17, 2023. View the NCCN Guidelines Find an NCCN Cancer for Patients free online Center near you NCCN.org/patientguidelines NCCN.org/cancercenters Connect with us NCCN Guidelines for Patients® Lung Cancer Screening, 2023 1 ...
患者为中心——肺癌患者具体应选择哪种治疗手段,还需要根据患者的身体情况、临床分期、病理和基因分型等综合判断,诊疗手段的创新最终都是服务于患者的预后和生存质量,愿新的疗法在2023 年为患者带来更多惊喜。 参考文献: [1].NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines®)Non-Small Cell Lung ...
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Small Cell Lung Cancer. Version 3.2023 撰写:Squid 审校:Babel 排版:Squid 执行:Squid 医脉通是专业的在线医生平台,“感知世界医学脉搏,助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「...
2023.V5-2023年11月8日 。; NCCNNSCLC指南从2022.v6版到2023.v1版的更新包括: DIAG-A2/3 ·第2项;第2子项修改:关于疑似I至III期肺癌的最佳诊断步骤的决定,应由胸部放射科医生、介入放射科医生、和胸外科医生,以及主攻胸腔肿瘤学的肺科医生决定。多学科评估还应该包括具有先进支气管镜技术专长的肺科医生或胸...
NCCN 肺癌筛查2023报告.pdf,NCCN GUIDELINES FOR PATIENTS® Lung Cancer Screening 邓no心\I. COMPREHENSIVE CANCER NETWORK Available online at Presented with support from FOUNDATION NCCN.orq/patientquid创们es Guiding Treatment. Changing Lives. 。 [ Lung Can
SummaryofGuidelinesUpdates thebestmanagementforanypatient LungCancerPreventionandScreening(PREV-1)withcancerisinaclinicaltrial. ClinicalPresentationandRiskAssessment(DIAG-1)Participationinclinicaltrialsis InitialEvaluationandClinicalStage(NSCL-1)especiallyencouraged. EvaluationandTreatment: FindanNCCNMemberInstitution: St...